Sign inCreate account

Report workspace tools

NCT06154707UNKNOWNanonymous

Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

Sponsor

Source record

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Osteoporosis and Sarcopenia

Indication / condition

AI-normalized

Sarcopenia

Intervention

Source record

Denosumab Injection, Normal saline injection (1.0ml/ branch)

Source & freshness

Source record

NCT ID

NCT06154707

Original source

ClinicalTrials.gov

Source last updated

Aug 16, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06154707

Title

Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

UNKNOWN

Phase

PHASE3

Condition raw

Sarcopenia

Condition normalized

Sarcopenia

Modality raw

Sarcopenia

Modality normalized

monoclonal antibody

Target raw

Osteoporosis and Sarcopenia

Target normalized

Osteoporosis and Sarcopenia

Interventions

Denosumab Injection, Normal saline injection (1.0ml/ branch)

Public preview

Source record

This clinical trial aims to evaluate the efficacy of Denosumab in treating osteoporosis and its impact on sarcopenia in a domestic population. The study involves a randomized controlled design with an estimated enrollment of 86 participants, comparing Denosumab treatment against a placebo over a 12-month period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06154707

Status

UNKNOWN

Phase

PHASE3

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Executive brief

Investment-Ready Snapshot

This clinical trial aims to evaluate the efficacy of Denosumab in treating osteoporosis and its impact on sarcopenia in a domestic population. The study involves a randomized controlled design with an estimated enrollment of 86 participants, comparing Denosumab treatment against a placebo over a 12-month period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 16, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06154707

Indication

Sarcopenia

Modality

monoclonal antibody

Target

Osteoporosis and Sarcopenia

Intervention

Denosumab Injection, Normal saline injection (1.0ml/ branch)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.